急性髓系白血病中白血病干细胞的生物标志物
The biomarkers of leukemia stem cells in acute myeloid leukemia.
作者信息
Ding Yahui, Gao Huier, Zhang Quan
机构信息
State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, China.
State Key Laboratory of Experimental Hematology, Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China.
出版信息
Stem Cell Investig. 2017 Mar 2;4:19. doi: 10.21037/sci.2017.02.10. eCollection 2017.
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by morphology and chromosome aberrations with high mortality. Leukemia stem cells (LSCs) in AML played important roles in leukemia initiation, progression, and were considered to be the root of chemotherapeutic drug resistance and disease relapse. The identification and targeting LSCs depended on membrane markers like CD34, CD38, CD123, TIM3, CD25, CD32 and CD96. In addition, the transcription factors were also therapeutic targets in eradicating LSCs, such as histone deacetylases (HDACs), NF-κB, HIF-1α and β-catenin. Besides membrane markers and transcription factors, intracellular reactive oxygen species (ROS), telomerase and microRNAs were identified to be new targets for ablating LSCs in AML.
急性髓系白血病（AML）是一种异质性疾病，其特征为形态学和染色体畸变，死亡率高。AML中的白血病干细胞（LSCs）在白血病的起始、进展中起重要作用，被认为是化疗耐药和疾病复发的根源。LSCs的鉴定和靶向依赖于CD34、CD38、CD123、TIM3、CD25、CD32和CD96等膜标志物。此外，转录因子也是根除LSCs的治疗靶点，如组蛋白去乙酰化酶（HDACs）、核因子κB（NF-κB）、缺氧诱导因子-1α（HIF-1α）和β-连环蛋白。除了膜标志物和转录因子外，细胞内活性氧（ROS）、端粒酶和微小RNA被确定为AML中消除LSCs的新靶点。
Zotero 插件